The future of immunisation policy, implementation, and financing

Orin S. Levine, David E. Bloom, Thomas Cherian, Ciro De Quadros, Samba Sow, John Wecker, Philippe Duclos, Brian Greenwood

Research output: Contribution to journalReview article

Abstract

Vaccines have already saved many lives and they have the potential to save many more as increasingly elaborate technologies deliver new and effective vaccines against both infectious diseases - for which there are currently no effective licensed vaccines - such as malaria, tuberculosis, and HIV and non-infectious diseases such as hypertension and diabetes. However, these new vaccines are likely to be more complex and expensive than those that have been used so effectively in the past, and they could have a multifaceted effect on the disease that they are designed to prevent, as has already been seen with pneumococcal conjugate vaccines. Deciding which new vaccines a country should invest in requires not only sound advice from international organisations such as WHO but also a well informed national immunisation advisory committee with access to appropriate data for local disease burden. Introduction of vaccines might need modification of immunisation schedules and delivery procedures. Novel methods are needed to finance the increasing number of new vaccines that have the potential to save lives in countries that are too poor to afford them. Here, we discuss some options.

Original languageEnglish (US)
Pages (from-to)439-448
Number of pages10
JournalThe Lancet
Volume378
Issue number9789
DOIs
StatePublished - Jul 30 2011
Externally publishedYes

Fingerprint

Immunization
Vaccines
Immunization Schedule
Conjugate Vaccines
Pneumococcal Vaccines
Advisory Committees
Malaria
Communicable Diseases
Tuberculosis
HIV
Organizations
Hypertension
Technology

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Levine, O. S., Bloom, D. E., Cherian, T., De Quadros, C., Sow, S., Wecker, J., ... Greenwood, B. (2011). The future of immunisation policy, implementation, and financing. The Lancet, 378(9789), 439-448. https://doi.org/10.1016/S0140-6736(11)60406-6

The future of immunisation policy, implementation, and financing. / Levine, Orin S.; Bloom, David E.; Cherian, Thomas; De Quadros, Ciro; Sow, Samba; Wecker, John; Duclos, Philippe; Greenwood, Brian.

In: The Lancet, Vol. 378, No. 9789, 30.07.2011, p. 439-448.

Research output: Contribution to journalReview article

Levine, OS, Bloom, DE, Cherian, T, De Quadros, C, Sow, S, Wecker, J, Duclos, P & Greenwood, B 2011, 'The future of immunisation policy, implementation, and financing', The Lancet, vol. 378, no. 9789, pp. 439-448. https://doi.org/10.1016/S0140-6736(11)60406-6
Levine OS, Bloom DE, Cherian T, De Quadros C, Sow S, Wecker J et al. The future of immunisation policy, implementation, and financing. The Lancet. 2011 Jul 30;378(9789):439-448. https://doi.org/10.1016/S0140-6736(11)60406-6
Levine, Orin S. ; Bloom, David E. ; Cherian, Thomas ; De Quadros, Ciro ; Sow, Samba ; Wecker, John ; Duclos, Philippe ; Greenwood, Brian. / The future of immunisation policy, implementation, and financing. In: The Lancet. 2011 ; Vol. 378, No. 9789. pp. 439-448.
@article{cee4b078c45246eda89c2ac25774bf33,
title = "The future of immunisation policy, implementation, and financing",
abstract = "Vaccines have already saved many lives and they have the potential to save many more as increasingly elaborate technologies deliver new and effective vaccines against both infectious diseases - for which there are currently no effective licensed vaccines - such as malaria, tuberculosis, and HIV and non-infectious diseases such as hypertension and diabetes. However, these new vaccines are likely to be more complex and expensive than those that have been used so effectively in the past, and they could have a multifaceted effect on the disease that they are designed to prevent, as has already been seen with pneumococcal conjugate vaccines. Deciding which new vaccines a country should invest in requires not only sound advice from international organisations such as WHO but also a well informed national immunisation advisory committee with access to appropriate data for local disease burden. Introduction of vaccines might need modification of immunisation schedules and delivery procedures. Novel methods are needed to finance the increasing number of new vaccines that have the potential to save lives in countries that are too poor to afford them. Here, we discuss some options.",
author = "Levine, {Orin S.} and Bloom, {David E.} and Thomas Cherian and {De Quadros}, Ciro and Samba Sow and John Wecker and Philippe Duclos and Brian Greenwood",
year = "2011",
month = "7",
day = "30",
doi = "10.1016/S0140-6736(11)60406-6",
language = "English (US)",
volume = "378",
pages = "439--448",
journal = "The Lancet",
issn = "0140-6736",
publisher = "Elsevier Limited",
number = "9789",

}

TY - JOUR

T1 - The future of immunisation policy, implementation, and financing

AU - Levine, Orin S.

AU - Bloom, David E.

AU - Cherian, Thomas

AU - De Quadros, Ciro

AU - Sow, Samba

AU - Wecker, John

AU - Duclos, Philippe

AU - Greenwood, Brian

PY - 2011/7/30

Y1 - 2011/7/30

N2 - Vaccines have already saved many lives and they have the potential to save many more as increasingly elaborate technologies deliver new and effective vaccines against both infectious diseases - for which there are currently no effective licensed vaccines - such as malaria, tuberculosis, and HIV and non-infectious diseases such as hypertension and diabetes. However, these new vaccines are likely to be more complex and expensive than those that have been used so effectively in the past, and they could have a multifaceted effect on the disease that they are designed to prevent, as has already been seen with pneumococcal conjugate vaccines. Deciding which new vaccines a country should invest in requires not only sound advice from international organisations such as WHO but also a well informed national immunisation advisory committee with access to appropriate data for local disease burden. Introduction of vaccines might need modification of immunisation schedules and delivery procedures. Novel methods are needed to finance the increasing number of new vaccines that have the potential to save lives in countries that are too poor to afford them. Here, we discuss some options.

AB - Vaccines have already saved many lives and they have the potential to save many more as increasingly elaborate technologies deliver new and effective vaccines against both infectious diseases - for which there are currently no effective licensed vaccines - such as malaria, tuberculosis, and HIV and non-infectious diseases such as hypertension and diabetes. However, these new vaccines are likely to be more complex and expensive than those that have been used so effectively in the past, and they could have a multifaceted effect on the disease that they are designed to prevent, as has already been seen with pneumococcal conjugate vaccines. Deciding which new vaccines a country should invest in requires not only sound advice from international organisations such as WHO but also a well informed national immunisation advisory committee with access to appropriate data for local disease burden. Introduction of vaccines might need modification of immunisation schedules and delivery procedures. Novel methods are needed to finance the increasing number of new vaccines that have the potential to save lives in countries that are too poor to afford them. Here, we discuss some options.

UR - http://www.scopus.com/inward/record.url?scp=79960897597&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79960897597&partnerID=8YFLogxK

U2 - 10.1016/S0140-6736(11)60406-6

DO - 10.1016/S0140-6736(11)60406-6

M3 - Review article

C2 - 21664676

AN - SCOPUS:79960897597

VL - 378

SP - 439

EP - 448

JO - The Lancet

JF - The Lancet

SN - 0140-6736

IS - 9789

ER -